Articles by Kim Huynh-Ba - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe
  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Kim Huynh-Ba

Kim Huynh-Ba

Technical Director of PHARMALYTIK

Kim Huynh-Ba is the Technical Director of PHARMALYTIK.
Articles
Pharmaceutical Stability: Scientific and Regulatory Considerations for Global Drug Development and Commercialization
November 3, 2012
By: Dilip R. Choudhury , Ramesh K. Sood , John Bobiak , Mark Alasandro , Steven W. Baertschi , Bekki Komas , M. J. Skibic , Brian W. Pack , Saji Thomas , Robert H. Seevers , Kim Huynh-Ba , Stephen Colgan , Robert J. Timpano , Ganapathy Mohan , David Lin

A two-day workshop on the "science behind pharmaceutical stability" was held in conjunction with the Annual Meeting of American Association of Pharmaceutical Scientists (AAPS) on Oct. 21-22, 2011 in Washington, DC.
AAPS Workshop Summary
November 2, 2012
By: Dilip R. Choudhury , Ramesh K. Sood , John Bobiak , Mark Alasandro , Steven W. Baertschi , Bekki Komas , M. J. Skibic , Brian W. Pack , Saji Thomas , Robert H. Seevers , Kim Huynh-Ba , Stephen Colgan

A two-day workshop on the "science behind pharmaceutical stability" was held in conjunction with the Annual Meeting of American Association of Pharmaceutical Scientists (AAPS) on Oct. 21-22, 2011 in Washington, DC.
Highlights of "Current Drug Product Stability Issues"
December 27, 2006
By: Kim Huynh-Ba , Eric Nelson

Symposium held at 2006 AAPS Annual Meeting in San Antonio

ADVERTISEMENT
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
15%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FindPharma Custom Search
Featured Jobs

More Jobs
Click here